Viscoelastic collagen solution for ophthalmic use and method of preparation

Claim 2

A chemically-modified collagen compound which comprises at least two native collagen molecules which are coupled at at least one lysine epsilon amino group present on each said collagen molecule by a coupling group, said coupling group comprising at least two moieties selected from the group consisting of carbonyl and sulfonyl groups.

Claim 3

The chemically-modified collagen compound of claim 1 wherein said carbonyl and/or sulfonyl groups present in said coupling group are linked to each other through saturated or unsaturated alkylene, arylene or mixed alkylene-arylene coupling chains having less than about twenty carbon atoms, wherein said alkylene and/or arylene coupling chains may also contain heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and may be substituted in available aromatic positions by carboxyl groups, straight or branched chain alkyl groups of about 1 to 4 carbon atoms, straight or branched chain alkoxy groups of about 1 to 4 carbon atoms, halogens and other non-reactive moieties, and in available aliphatic positions by carboxyl groups and alkyl or alkoxy groups of about 1 to 4 carbon atoms.

Claim 4

The chemically-modified collagen compound of claim 1 wherein said coupling group has the general formula: --B--A--B-- wherein B is independently CO, SO 2 or combinations thereof; and A is selected from the group consisting of: (1) an aromatic group having about 6 to 20 carbon atoms; ##STR6## wherein Ar is independently selected from the group consisting of an aromatic ring having 6 to 10 carbon atoms, a heteroaromatic ring containing atoms selected from the group consisting of C, N, O and S, and having about 5 to 10 atoms, or combinations thereof; J is hydrogen or --L-- b B, wherein L is selected from the group consisting of phenylene, an alkylene of about 1 to 4 carbon atoms, and an oxyalkylene of about 1 to 4 carbon atoms, b is 0 or 1, and B is as defined hereinabove, with the proviso that only one J in the chain ##STR7## may be --L -- b B, with all other J's being hydrogen; n is 0 or 1; a is 0 or an integer having a value of between about 1 and 4; and D is independently selected from the group consisting of O, CO, S, SO, SO 2 , ##STR8## --SO 2 --NH--, --NH--CO--NH--, wherein m is an integer having a value of between about 1 and 3, R is selected from the group consisting of phenyl, and a straight or branched chain alkyl or acyl group having 1 to 4 carbon atoms; and J is as defined and restricted hereinabove; (3) an aromatic group having about 6 to 10 carbon atoms, wherein said aromatic group may be substituted in available positions by J wherein J is as defined and restricted hereinabove; (4) a heteroaromatic group containing atoms selected from the group consisting of C, N, O and S, and having from about 5 to 14 ring atoms, wherein said heteroaromatic group may be substituted in available positions by J, wherein J is as defined and restricted hereinabove; (5) an aliphatic or arylaliphatic chain which contains one or two olefinic or acetylenic groups and which contains about 2 to 20 carbon atoms, wherein said chain may be substituted in available positions by J, wherein J is as defined and restricted hereinabove; (6) an alicyclic ring which may be partially unsaturated, having about 3 to 15 carbon atoms, wherein said alicyclic ring may be substituted in available positions by J wherein J is as defined and restricted hereinabove; (7) a heterocyclic ring which may be saturated or unsaturated and which contains atoms selected from the group consisting of C, N, O and S, and which has from about 5 to 12 ring atoms, wherein said heterocyclic ring may be substituted in available positions by J wherein J is as defined and restricted hereinabove; ##STR9## wherein t is an integer having a value of between about 1 and 8; E is independently selected from the group consisting of O, NRJ, S, SO, SO 2 , CO, ##STR10## CONH, SO 2 NH and NHCONH, wherein R is as defined hereinabove, and m is an integer having a value of between about 1 and 3; J is as defined and restricted hereinabove; s is an integer having a value of between about 2 and 8; p is 0 or an integer having a value of between about 1 and 4; q is about 0 or 1; and r is 0 or an integer having a value of between about 1 and 8, provided that when q is 1, r is greater than 0; and ##STR11## wherein G is independently selected from the group consisting of an aromatic ring having about 6 to 10 carbon atoms, a heteroaromatic ring having about 5 to 10 atoms, and a heterocyclic ring having about 5 to 10 atoms, wherein the heteroaromatic and heterocyclic rings contain atoms selected from the group consisting of C, N, O and S; J is as defined and restricted hereinabove; w is an integer having a value of between about 1 and 8; E and q are as defined hereinabove; y is about 1 or 2; and v is 0 or an integer having a value of between about 1 and 4, provided that when q is 1, v is not 0.

Claim 5

The chemically-modified collagen compound of claim 3 wherein A is selected from the group consisting of: ##STR12##

Claim 6

The chemically-modified collagen compound of claim 3 wherein B is CO and A is --CH 2 -- 2 .

Claim 7

The chemically-modified collagen compound of claim 1 wherein at least a portion of the lysine epsilon amino groups which are not linked to said coupling groups are linked to amine-modifying groups, which amine-modifying groups are selected from the group consisting of saturated or unsaturated alkane sulfonamide and carboxamide groups, arene sulfonamide and carboxamide groups and mixed saturated or unsaturated alkane-arene sulfonamide and carboxamide groups, which amine-modifying groups have between about 2 and 20 carbon atoms and are terminated by one or two carboxylic or sulfonic acid moieties, wherein said amine-modifying group may also contain up to 5 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and may be substituted in available aromatic and aliphatic positions by carboxyl groups, alkyl and alkoxy groups having about 1 to 4 carbon atoms and halogens.

Claim 8

The chemically-modified collagen compound of claim 1 wherein at least about 60 percent of the lysine epsilon amino groups which are not linked to said coupling groups are linked to amine-modifying groups, which amine-modifying groups are selected from the group consisting of saturated or unsaturated alkane sulfonamide and carboxamide groups, arene sulfonamide and carboxamide groups and mixed saturated or unsaturated alkane-arene sulfonamide and carboxamide groups, which amine-modifying groups have between about 2 and 20 carbon atoms and are terminated by one or two carboxylic or sulfonic acid moieties, wherein said amine-modifying group may also contain up to 5 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and may be substituted in available aromatic and aliphatic positions by carboxyl groups, alkyl and alkoxy groups having about 1 to 4 carbon atoms and halogens.

Claim 9

A collagen fraction comprised of collagen molecules, about 10 to 80 percent of which comprise the chemically-modified collagen compound of claim 1, with all of the remaining collagen molecules being uncoupled.

Claim 10

A collagen fraction comprised of collagen molecules, about 10 to 80 percent of which comprise the chemically-modified collagen compound of claim 7.

Claim 11

A viscoelastic collagen solution comprising about 0.5 to 5.0 percent by weight of the collagen fraction of claim 9 dissolved in a physiological buffer solution.

Claim 12

A viscoelastic collagen solution comprising about 0.5 to 5.0 percent by weight of the collagen compound of claim 6 dissolved in a physiological buffer solution, wherein the coupling group is present in said chemically-modified collagen compound to such an extent that a 2 percent by weight solution of said collagen compound in said physiological buffer has a steady state viscosity of about 0.15 to 10 6 to about 4.0×10 6 centipoise at a shear rate of about 0.10 seconds -1 ; a steady state viscosity of about 0.20×10 5 to about 7.5×10 5 centipoise at a shear rate of about 1.0 seconds -1 ; a steady state viscosity of about 0.3×10 4 to about 1.0×10 5 centipoise at a shear rate of about 10.0 seconds -1 ; and a steady state viscosity of about 0.45×10 3 to about 2.0×10 4 centipoise at a shear rate of about 100 seconds -1 .

Claim 13

A viscoelastic collagen solution comprising about 0.5 to 5.0 percent by weight of the collagen compound of claim 6 dissolved in a physiological buffer solution, wherein the coupling group is present in said chemically-modified collagen compound to such an extent that a 2 percent by weight solution of said collagen compound in said physiological buffer has a melt temperature of between about 32° C. and 48° C.

Claim 14

The viscoelastic collagen solution of claim 11 wherein said coupling group is --CO--CH 2 ) 2 --CO--, and said modifying group is --CO--CH 2 -- 2 CO 2 H.

Claim 15

The viscoelastic collagen solution of claim 11 wherein said coupling group is --CO--CH 2 ) 3 --CO 2 H. modifying group is --CO(CH 2 ) 3 --CO 2 H.

Claim 18

The method of claim 15 wherein said coupling agent is selected from the group consisting of terephthaloyl chloride; bicyclo-(2,2,2)-oct-7-ene-2,3,5,6-tetracarboxylic-2,3,5,6-dianhydride; 1,2,4,5-benzenetetracarboxylic dianhydride; p-fluorosulfonylbenzenesulfonyl chloride; and wherein the pH of the reaction mixture is initially maintained at about 3 to about 5.5 before raising the pH to above about 8.

Claim 19

The method of claim 15 wherein said method additionally comprises the steps of: (c) adding to said reaction mixture a mono-reactive amine-modifying agent, said amine-modifying agent being selected from the group consisting of anhydrides, acid halides, sulfonyl halides and active esters, in an amount equal to at least about 100 moles of amine-modifying agent per mole of native collagen; and (d) conducting the amine-modification reaction at a pH of greater than about 8 and at a temperature of between about 0° and 35° C., for a time period sufficient to either react or hydrolyze substantially all of said amine-modifying agent.

Claim 24

A method of replacing at least a portion of the aqueous or vitreous humor in a human or animal eye, said method comprising introducing into the aqueous or vitreous chamber of said human or animal eye, an effective amount of the viscoelastic collagen solution of claim 12.

Claim 25

A method of inserting an intraocular lens into the anterior or posterior chamber of a human or animal eye, said method comprising introducing into said anterior or posterior chamber an amount of the viscoelastic solution of claim 12 sufficient to reduce the trauma which normally results from inserting an intraocular lens into said chamber without the use of a viscoelastic ophthalmic aid.

Claim 26

A method of preventing fibrous tissue formation and consequent development of adhesion and scars which may occur in healing tissue during the normal healing process, said method comprising introducing into a surgical site, either during surgery or post-operatively an effective amount of the viscoelastic solution of claim 12.

Claim 27

A method of reducing inflammation and promoting the normal healing of soft tissues and cartilage, said method comprising introducing by injection into the affected soft tissue or cartilage an effective amount of the viscoelastic solution of claim 12.

Claim 28

A method of enhancing normal joint and tendon function in a human or animal by lubricating said joint or tendon, said method comprising introducing into the synovial space associated with said joint or tendon an effective lubricating amount of the viscoelastic solution of claim 12.

Claim 29

A method of separating healing tissues and maintaining said separation during the normal healing process after surgery, said method comprising introducing into a surgical site, either during surgery or post-operatively, an effective amount of the viscoelastic solution of claim 12.

Claim 30

A method of protecting a layer of tissue during surgery on an adjacent layer of tissue, said method comprising introducing into the surgical site an amount of the viscoelastic solution of claim 12 effective to prevent dislocation and movement of said tissue.

Claim 31

A method of protecting soft tissue and cartilage from the possible harmful effects of prosthetic implants, said method comprising coating said implant with an effective lubricating amount of the viscoelastic solution of claim 12.

Claim 32

A method of achieving hemostasis comprising placing an effective amount of the chemically-modified collagen compound of claim 1 in contact with a bleeding wound.

Claim 33

A method of achieving hemostasis comprising placing an effective amount of the chemically-modified collagen compound of claim 7 in contact with a bleeding wound.

Claim 34

A method of augmenting soft tissue comprising placing an effective amount of the chemically-modified collagen compound of claim 1 in contact with the augmentation site.

Claim 35

A method of augmenting soft tissue comprising placing an effective amount of the chemically-modified collagen compound of claim 7 in contact with the augmentation site.